The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity
Open accessAbstract
BACKGROUND: Proton radiotherapy (PRT) is an emerging treatment for prostate cancer despite limited knowledge of clinical benefit or potential harms compared with other types of radiotherapy. We therefore compared patterns of PRT use, cost, and early toxicity among Medicare beneficiaries with prostate cancer with those of intensity-modulated radiotherapy (IMRT). METHODS: We performed a retrospective study of all Medicare beneficiaries aged greater than or equal to 66 years who received PRT or IMRT for prostate cancer during 2008 and/or 2009. We used multivariable logistic regression to identify factors associated with receipt of PRT. To assess toxicity, each PRT patient was matched with two IMRT patients with similar clinical and sociodemographic characteristics. The main outcome measures were receipt of PRT or IMRT, Medicare reimbursement for each treatment, and early genitourinary, gastrointestinal, and other toxicity. All statistical tests were two-sided. RESULTS: We identified 27,647 men; 553 (2%) received PRT and 27,094 (98%) received IMRT. Patients receiving PRT were younger, healthier, and from more affluent areas than patients receiving IMRT. Median Medicare reimbursement was $32,428 for PRT and $18,575 for IMRT. Although PRT was associated with a statistically significant reduction in genitourinary toxicity at 6 months compared with IMRT (5.9% vs 9.5%; odds ratio [OR] = 0.60, 95% confidence interval [CI] = 0.38 to 0.96, P = .03), at 12 months post-treatment there was no difference in genitourinary toxicity (18.8% vs 17.5%; OR = 1.08, 95% CI = 0.76 to 1.54, P = .66). There was no statistically significant difference in gastrointestinal or other toxicity at 6 months or 12 months post-treatment. CONCLUSIONS: Although PRT is substantially more costly than IMRT, there was no difference in toxicity in a comprehensive cohort of Medicare beneficiaries with prostate cancer at 12 months post-treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comorbidity measures for use with administrative data.
Elixhauser, A., Steiner, C., Harris, D. R., & Coffey, R. M. (1998) · Medical Care · doi:10.1097/00005650-199801000-00004 · Cited by 9,921
Cited by
Carbon ion radiotherapy in Japan: an assessment of 20 years of clinical experience
Kamada, T., Tsujii, H., Blakely, E. A., Debus, J., De Neve, W., Durante, M., Jäkel, O., Mayer, R., Orecchia, R., Pötter, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70412-7 · Cited by 562
Charged-particle therapy in cancer: clinical uses and future perspectives
Durante, M., Orecchia, R., & Loeffler, J. S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.30 · Cited by 484
Charged particle therapy—optimization, challenges and future directions
Loeffler, J. S., & Durante, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.79 · Cited by 426
Nuclear physics in particle therapy: a review
Durante, M., & Paganetti, H. (2016) · Reports on Progress in Physics · doi:10.1088/0034-4885/79/9/096702 · Cited by 345
Safety of combining radiotherapy with immune-checkpoint inhibition
Hwang, W. L., Pike, L. R. G., Royce, T. J., Mahal, B. A., & Loeffler, J. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0046-7 · Cited by 295
Metadata
- Authors
- Yu, J. B., Soulos, P. R., Herrin, J., Cramer, L. D., Potosky, A. L., Roberts, K. B., & Gross, C. P.
- Venue
- JNCI: Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-12-29
- Volume
- 105
- Issue
- 1
- Pages
- 25-32
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W3144729699
- Cited by
- 173
- References
- 1
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. https://app.cochat.ai/papers/10.1093/jnci/djs463
- The paper
- Yu, J. B., Soulos, P. R., Herrin, J., Cramer, L. D., Potosky, A. L., Roberts, K. B., & Gross, C. P. (2013). Proton Versus Intensity-Modulated Radiotherapy for Prostate Cancer: Patterns of Care and Early Toxicity. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djs463
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.